PURPOSE: (90)Y-labelled compounds used in targeted radiotherapy are usually imaged with SPECT by recording the bremsstrahlung X-rays of the beta decay. The continuous shape of the X-ray spectrum induces the presence of a significant fraction of scatter rays in the acquisition energy window, reducing the accuracy of biodistribution and of dosimetry assessments. METHODS: The aim of this paper is to use instead the low branch of e(-) e(+) pair production in the (90)Y decay. After administration of (90)Y-labelled SIR-Spheres by catheterization of both liver lobes, the activity distribution is obtained by (90)Y time-of-flight (TOF) PET imaging. The activity distribution is convolved with a dose irradiation kernel in order to derive the regional dosimetry distribution. RESULTS: Evaluation on an anatomical phantom showed that the method provided an accurate dosimetry assessment. Preliminary results on a patient demonstrated a high-resolution absorbed dose distribution with a clear correlation with tumour response. CONCLUSION: This supports the implementation of (90)Y PET in selective internal radiation therapy of the liver.
PURPOSE: (90)Y-labelled compounds used in targeted radiotherapy are usually imaged with SPECT by recording the bremsstrahlung X-rays of the beta decay. The continuous shape of the X-ray spectrum induces the presence of a significant fraction of scatter rays in the acquisition energy window, reducing the accuracy of biodistribution and of dosimetry assessments. METHODS: The aim of this paper is to use instead the low branch of e(-) e(+) pair production in the (90)Y decay. After administration of (90)Y-labelled SIR-Spheres by catheterization of both liver lobes, the activity distribution is obtained by (90)Y time-of-flight (TOF) PET imaging. The activity distribution is convolved with a dose irradiation kernel in order to derive the regional dosimetry distribution. RESULTS: Evaluation on an anatomical phantom showed that the method provided an accurate dosimetry assessment. Preliminary results on a patient demonstrated a high-resolution absorbed dose distribution with a clear correlation with tumour response. CONCLUSION: This supports the implementation of (90)Y PET in selective internal radiation therapy of the liver.
Authors: Barry W Wessels; Mark W Konijnenberg; Roger G Dale; Hazel B Breitz; Marta Cremonesi; Ruby F Meredith; Alan J Green; Lionel G Bouchet; A Bertrand Brill; Wesley E Bolch; George Sgouros; Stephen R Thomas Journal: J Nucl Med Date: 2008-10-16 Impact factor: 10.057
Authors: M de Jong; W H Bakker; E P Krenning; W A Breeman; M E van der Pluijm; B F Bernard; T J Visser; E Jermann; M Béhé; P Powell; H R Mäcke Journal: Eur J Nucl Med Date: 1997-04
Authors: Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar Journal: Eur J Nucl Med Mol Imaging Date: 2011-03-11 Impact factor: 9.236
Authors: Michael Wissmeyer; Susanne Heinzer; Pietro Majno; Franz Buchegger; Habib Zaidi; Valentina Garibotto; Magalie Viallon; Christoph D Becker; Osman Ratib; Sylvain Terraz Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-06 Impact factor: 9.236
Authors: Se Young Chun; Minh Phuong Nguyen; Thanh Quoc Phan; Hanvit Kim; Jeffrey A Fessler; Yuni K Dewaraja Journal: IEEE Trans Med Imaging Date: 2019-10-23 Impact factor: 10.048